Trial
NCT04751383
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
High Risk Neuroblastoma
Intervention
Biospecimen Collection
Why stopped
Drug supply issues
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-30